BACKGROUND: Prevention of chemotherapy-induced nausea and vomiting (CINV) can be 
improved with guideline-consistent use of antiemetics. However, adherence to 
antiemetic guidelines remains often insufficient. Therefore, new strategies that 
improve adherence are needed.
OBJECTIVES: To review the latest antiemetic guideline recommendations and 
provide an update on the use of NEPA, a fixed combination antiemetic composed of 
the neurokinin-1 receptor antagonist (RA) netupitant and the 
5-hydroxytryptamine-3 RA palonosetron (Akynzeo®).
METHODS: Analysis of the literature was performed, including guidelines, 
published literature, congress data on NEPA, and relevant articles on CINV.
FINDINGS: Nurses are in a unique position to promote guideline-consistent 
antiemetic prophylaxis and are central in the education of patients and 
caregivers. Thus, nurses’ continuous education on antiemetic treatments is key 
for the prevention and management of CINV. NEPA offers a simplified antiemetic 
therapy with the potential to increase guideline adherence.